Skip to content

The Role of Amniotic Membrane Transplantation in Ocular Chemical Burns

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00370812
Enrollment
90
Registered
2006-09-01
Start date
2006-07-31
Completion date
2009-01-31
Last updated
2008-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Burns

Keywords

amniotic membrane transplantation, ocular chemical burns

Brief summary

This is a randomized clinical trial study to identify the role of AMT (amniotic membrane transplantation) in treating epithelial defect, symblepharon prevention preventing corneal vascularization and opacity decreasing pain and improving visual acuity, and patients with acute chemical burns.

Detailed description

The study is on patients with grade II-IV acute ocular chemical burns (Roper - Hall classification) in the first 2 weeks of injury. After topical anesthesia, all patients initially will receive first aid therapy; which included irrigation with normal saline to normalize ocular surface PH and removal of early particulate maeuil and debris. After complete examination and obtaining informed consent, the patients will be randomized using a treatment assignment list to either AMT with conventional medical therapy (group A) or medical treatment only (group B). In the patients with bilateral injuries the eyes will be randomized separately. AMT will be performed within 24h of presentation. amniotic membrane will remain in place for 7-14 days. The patients will be examined at days 1, 3, 7, 10, 14, 21, 28 and then biweekly until 3 months and monthly until (1 year in every visit, visual acuity (by sneillen charts), reduction of pain (subjectively) size of corneal epithelial defect (by fluorseein satiny extent of corneal vascularization and opacity, and symblepharon formation will be assessed. Digital photographs at each visit will be obtained.

Interventions

AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with chemical eye burn grade 2-4 * Burning has been occurred in 2 weeks

Exclusion criteria

* Grade I burnings * More than 2 weeks have passed of burning * Follow up of the patients has been disconnected in 6 month

Design outcomes

Primary

MeasureTime frame
Visual acuityDays 1, 3, 7, 10, 14, 21, 28 and then every 2weeks until 3 months and monthly until 1 year
PainDays 1, 3, 7, 10, 14, 21, 28 and then every 2weeks until 3 months and monthly until 1 year
Symblepharon formationDays 1, 3, 7, 10, 14, 21, 28 and then every 2weeks until 3 months and monthly until 1 year
Epithelial defect healingDays 1, 3, 7, 10, 14, 21, 28 and then every 2weeks until 3 months and monthly until 1 year
Corneal opacity and vascularizationDays 1, 3, 7, 10, 14, 21, 28 and then every 2weeks until 3 months and monthly until 1 year

Countries

Iran

Contacts

Primary ContactAlireza Baradaran Raffiee, MD
labbafi@hotmail.com+98 21 22587317

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026